GVK Biosciences has entered into a research agreement with Wyeth Pharmaceuticals, a division of Wyeth, to discover drug candidates focused on pre-defined discovery targets. GVK Bio will utilize in-house capabilities in discovery chemistry, informatics, biology and ADME to advance this programme.
GVK Bio will be responsible for identifying drug candidates, which will be transferred to Wyeth to advance these compounds towards clinical studies.
The details can be read here.
No comments:
Post a Comment